Table 1.
Patient and disease characteristics from the medical record abstraction, overall and by angioedema classification
| Patient characteristicsa | Total (n = 643) | Angioedema category | P valueb (yes vs no) | ||
|---|---|---|---|---|---|
| Yes (n = 259) | No (n = 173) | Misaligned (n = 211) | |||
| Age at enrolment (years) | .0906 | ||||
| Mean (SD) | 49.0 (15.56) | 49.4 (14.45) | 46.8 (16.50) | 50.4 (15.95) | |
| Min, Max | 19.0, 89.0 | 20.0, 81.0 | 19.0, 89.0 | 19.0, 87.0 | |
| Female sex (%) | 469 (72.9) | 197 (76.1) | 117 (67.6) | 155 (73.5) | .0540 |
| Race and ethnicityc | 544 | 205 | 155 | 184 | .5262 |
| Caucasian/White (%) | 491 (90.3) | 189 (92.2) | 138 (89.0) | 164 (89.1) | |
| Other (%) | 44 (8.1) | 15 (7.3) | 14 (9.0) | 15 (8.2) | |
| Data not available (%) | 9 (1.7) | 1 (0.5) | 3 (1.9) | 5 (2.7) | |
| Disease duration from diagnosis to enrolment (months) | .0486 | ||||
| Mean (SD) | 57.3 (77.73) | 61.7 (76.64) | 46.1 (69.06) | 61.0 (85.43) | |
| Comorbid conditions at enrolment (%) | |||||
| Hypersensitivity to NSAIDs | 52 (8.1) | 28 (10.8) | 10 (5.8) | 14 (6.6) | .0833 |
| Hashimoto's disease | 43 (6.7) | 27 (10.4) | 5 (2.9) | 11 (5.2) | .0042 |
| Asthma | 71 (11.0) | 33 (12.7) | 18 (10.4) | 20 (9.5) | .5434 |
| CSU/CIU severity at the time of diagnosis (%) | 642 | 259 | 173 | 210 | .0101 |
| Mild | 71 (11.1) | 27 (10.4) | 32 (18.5) | 12 (5.7) | |
| Moderate | 202 (31.5) | 81 (31.3) | 53 (30.6) | 68 (32.4) | |
| Severe | 233 (36.3) | 98 (37.8) | 45 (26.0) | 90 (42.9) | |
| Data not available | 136 (21.2) | 53 (20.5) | 43 (24.9) | 40 (19.0) | |
| UAS7TD | |||||
| Mean (SD) UAS7TD | 17.3 (10.46) | 17.6 (10.55) | 14.6 (8.97) | 19.2 (11.05) | .0032 |
| UAS7TD band (%) | 600 | 244 | 161 | 195 | .0140 |
| 0‐6 | 98 (16.3) | 41 (16.8) | 28 (17.4) | 29 (14.9) | |
| 7‐15 | 204 (34.0) | 75 (30.7) | 73 (45.3) | 56 (28.7) | |
| 16‐27 | 182 (30.3) | 82 (33.6) | 40 (24.8) | 60 (30.8) | |
| 28‐42 | 116 (19.3) | 46 (18.9) | 20 (12.4) | 50 (25.6) | |
CIU, chronic idiopathic urticaria; CSU, chronic spontaneous urticaria; Q1, first quartile; Q3, third quartile; MRA, medical record abstraction; NSAIDs, nonsteroidal anti‐inflammatory drugs; SD, standard deviation; UAS7TD, Urticaria Activity Score over 7 Days, twice‐daily assessment.
For categorical variables, the total number of patients with nonmissing data is presented by angioedema category for each question along with “n (%)” for each possible response to the question. Except where otherwise noted, percentage denominators are the number of patients with nonmissing data for the applicable question.
P values shown from t tests for means of continuous variables and chi‐square tests for frequencies of categorical variables to compare patients who experience angioedema (Yes‐angioedema) with those who do not (No‐angioedema). Patients in the Misaligned category were not included in the statistical comparison. For race and ethnicity, due to the small number of patients in many of the race/ethnicity categories, all races other than white were combined for these comparisons. Patients whose race/ethnicity group is “data not available” were excluded from the statistical comparison.
Race and ethnicity data were not collected in France. For some categories of race and ethnicity, different terms were used across countries.